Home  |  Contact

Cellosaurus PER.C6 (CVCL_G704)

[Text version]

Cell line name PER.C6
Synonyms Per.C6; PER C6; PERC6; PerC6; Perc6; PER cell clone 6
Accession CVCL_G704
Resource Identification Initiative To cite this cell line use: PER.C6 (RRID:CVCL_G704)
Comments Group: Patented cell line.
Group: Vaccine production cell line.
From: Johnson & Johnson Janssen (originally Crucell).
Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 96022940.
Biotechnology: Used for the production of follitropin delta (Trade name: Rekovelle).
Transformant: NCBI_TaxID; 28285; Adenovirus 5 [E1A/E1B].
Misspelling: Per.Co6; Occasionally.
Derived from sampling site: Fetal eye; retina; retinoblast.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_A9E7 (HP PER.C6)CVCL_A7ME (PER.C6 TetR)
Originate from same individual CVCL_1K15 ! 911
Sex of cell Sex unspecified
Age at sampling 18FW
Category Transformed cell line
Web pages https://web.archive.org/web/20140721200546/http://www.crucell.com/page/downloads/Factsheet_PER.C6_Technology.pdf
https://web.archive.org/web/20121219090924/http://www.dsm.com/en_US/downloads/dpp/PER.C6_Brochure.pdf
https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/p/cell-lines-detail-452.html
Publications

PubMed=9741429; DOI=10.1089/hum.1998.9.13-1909
Fallaux F.J., Bout A., van der Velde I., van den Wollenberg D.J.M., Hehir K.M., Keegan J., Auger C., Cramer S.J., van Ormondt H., van der Eb A.J., Valerio D., Hoeben R.C.
New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses.
Hum. Gene Ther. 9:1909-1917(1998)

PubMed=11257414; DOI=10.1016/S0264-410X(00)00508-9
Pau M.G., Ophorst C., Koldijk M.H., Schouten G., Mehtali M., Uytdehaag F.
The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines.
Vaccine 19:2716-2721(2001)

Patent=US6602706
Fallaux F.J., Hoeben R.C., van der Eb A.J., Bout A., Valerio D.
Packaging systems for human recombinant adenovirus to be used in gene therapy.
Patent number US6602706, 05-Aug-2003

PubMed=16566444
Lewis J.A., Brown E.L., Duncan P.A.
Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines.
Dev. Biol. (Basel) 123:165-176(2006)

PubMed=18052336; DOI=10.1021/bp070258u
Berdichevsky M., Gentile M.-P., Hughes B., Meis P., Peltier J., Blumentals I., Aunins J., Altaras N.E.
Establishment of higher passage PER.C6 cells for adenovirus manufacture.
Biotechnol. Prog. 24:158-165(2008)

PubMed=25903999; DOI=10.1002/biot.201400388
Genzel Y.
Designing cell lines for viral vaccine production: where do we stand?
Biotechnol. J. 10:728-740(2015)

Patent=US9469865
Zijlstra G.M., Hof R.P., Schilder J.
Process for the culturing of cells.
Patent number US9469865, 18-Oct-2016

PubMed=28450423; DOI=10.1530/EC-17-0067
Koechling W., Plaksin D., Croston G.E., Jeppesen J.V., Macklon K.T., Andersen C.Y.
Comparative pharmacology of a new recombinant FSH expressed by a human cell line.
Endocr. Connect. 6:297-305(2017)

Cross-references
Cell line databases/resources FCS-free; 39-13-46-1-8-11
Other Wikidata; Q54947225
Entry history
Entry creation11-Feb-2013
Last entry update23-Sep-2021
Version number18